Re-Sensitizing Tumor Cells to Cancer Drugs with Epigenetic Regulators

Area of Science:

• Oncology
• Epigenetics
• Cancer Therapeutics

Background:

• Cancer drug resistance, driven by genetic and epigenetic alterations, limits treatment efficacy.
• Epigenetic modifications play a crucial role in the development of resistance to conventional cancer therapies.
• Immune checkpoint therapies can also be affected by epigenetic changes in cancer cells.

Purpose of the Study:

• To review current data on epigenetic drugs and their targets in cancer therapy.
• To evaluate the potential of epigenetic modifiers in overcoming resistance to conventional and immune therapies.
• To explore drug repositioning strategies involving epigenetic modifiers for enhanced cancer treatment.

Main Methods:

• Literature review of studies on epigenetic drugs in cancer.
• Analysis of epigenetic mechanisms contributing to drug resistance.
• Examination of clinical data on epigenetic therapies and combinations.
• Evaluation of drug repositioning potential in conjunction with epigenetic modifiers.

Main Results:

• Epigenetic drugs modulate gene expression profiles, impacting cancer cell sensitivity.
• Combinations of epigenetic modifiers with conventional drugs can potentiate therapeutic effects.
• Epigenetic drugs can enhance the efficacy of immune checkpoint therapies.
• Repositioning approved drugs with epigenetic modifiers offers a viable treatment strategy.

Conclusions:

• Altering gene expression through epigenetic modifiers holds significant potential for improving cancer treatment outcomes.
• Epigenetic therapies represent a promising approach to circumventing drug resistance in various cancer types.
• Combination strategies involving epigenetic drugs are crucial for maximizing therapeutic benefits and improving patient survival.